Zobrazeno 1 - 10
of 143
pro vyhledávání: '"Claudio, Vernieri"'
Autor:
Anna Crispo, Livia S. A. Augustin, Assunta Luongo, Claudia Calderaio, Joao Breda, Sergio Coluccia, Alessandra Calabrese, Vittorio Marrazzo, Rosa Giannatiempo, Paola Trasacco, Elvira Palumbo, Sara Vitale, Giuseppe Porciello, Piergiacomo Di Gennaro, Roberta Caputo, Giuseppe Buono, Claudio Vernieri, Francesco Schettini, Maria Grimaldi, Flavia Nocerino, Egidio Celentano, Alfonso Amore, Mario Giuliano, Pietro De Placido, Carmine De Angelis, Roberto Bianco, Michelino De Laurentiis, Carlo La Vecchia, Grazia Arpino
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Obesity and metabolic disorders have been associated with poor outcomes in non-Mediterranean breast cancer (BC) patients. The purpose of this study was to investigate the prognostic potential of anthropometric variables in patients with earl
Externí odkaz:
https://doaj.org/article/f3a2ca9b48954ebe9d773daeec362742
Autor:
Sara Pusceddu, Francesca Corti, Natalie Prinzi, Federico Nichetti, Silva Ljevar, Adele Busico, Tommaso Cascella, Rita Leporati, Simone Oldani, Chiara Carlotta Pircher, Jorgelina Coppa, Veronica Resi, Massimo Milione, Marco Maccauro, Rosalba Miceli, Elena Tamborini, Federica Perrone, Carlo Spreafico, Monica Niger, Federica Morano, Filippo Pietrantonio, Ettore Seregni, Luigi Mariani, Vincenzo Mazzaferro, Giorgia Di Liberti, Giovanni Fucà, Filippo de Braud, Claudio Vernieri
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-5 (2023)
Abstract In retrospective studies, metformin use has been associated with better clinical outcomes in diabetic patients with advanced, well-differentiated neuroendocrine tumors (WDNETs). However, prospective evidence of metformin safety and activity
Externí odkaz:
https://doaj.org/article/1fcb7b069e624b61b3c438f1291779ca
Autor:
Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Adjuvant chemotherapy recommendations for ER+/HER2− early-stage breast cancers (eBC) involve integrating prognostic and predictive information which rely on physician judgment; this can lead to discordant recommendations. In this study we
Externí odkaz:
https://doaj.org/article/71af898d79424e0aa99424fea6092b45
Autor:
Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Chiara Corti, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Daniele Presti, Caterina Sposetti, Carlo Alberto Giorgi, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Daniele Generali, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2− aBC). Objectives: While CDK4/6i
Externí odkaz:
https://doaj.org/article/997ec44c91b244349cd2462f6a583683
Autor:
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fucà, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-5 (2023)
Abstract Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 pat
Externí odkaz:
https://doaj.org/article/1b8f8d9603654e7590deb24e3d8b863d
Autor:
Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, Giulia Montelatici, Angela Ficchì, Antonia Martinetti, Alessio Arata, Marta Del Vecchio, Claudia Lauria Pantano, Barbara Formisano, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri, Giovanni Fucà
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Advanced triple-negative breast cancer (aTNBC) has a poor prognosis; thus, there is a need to identify novel biomarkers to guide future research and improve clinical outcomes. Objectives: We tested the prognostic ability of an emerging, c
Externí odkaz:
https://doaj.org/article/d60a1af664724f99bf39ed7dd7ca1413
Autor:
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Elisabetta Munzone, Luana Lippolis, Martina Dameri, Francesco Ravera, Marco Colleoni, Giuseppe Viale, Luca Magnani, Alberto Ballestrero, Gabriele Zoppoli, Giancarlo Pruneri
Publikováno v:
PLoS Genetics, Vol 19, Iss 1, p e1010563 (2023)
BackgroundPrevious studies have provided a comprehensive picture of genomic alterations in primary and metastatic Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer (HR+ HER2- BC). However, the evol
Externí odkaz:
https://doaj.org/article/14b422e7ad2742c09e052fbd82eff010
Autor:
Serena Di Cosimo, Eliana La Rocca, Silva Ljevar, Maria Carmen De Santis, Marta Bini, Vera Cappelletti, Marta Valenti, Paolo Baili, Filippo G. de Braud, Secondo Folli, Gianfranco Scaperrotta, Chiara Volpi, Andrea Vingiani, Claudio Vernieri, Paolo Verderio, Rosalba Miceli, Giancarlo Pruneri
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Background: Previous data, mostly from clinical trials, reported that HER2-low status is associated with low pathological complete response (pCR), and favourable prognosis. Since these findings suggest the existence of an additional breast cancer sub
Externí odkaz:
https://doaj.org/article/c61dcae8ad024a518f451974ec2c145c
Autor:
Emma Zattarin, Federico Nichetti, Francesca Ligorio, Laura Mazzeo, Riccardo Lobefaro, Giovanni Fucà, Giorgia Peverelli, Andrea Vingiani, Giulia V. Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Extramammary Paget disease (EMPD) is a rare form of cutaneous, intraepithelial adenocarcinoma, which typically presents itself as an erythematous plaque originating from apocrine-gland rich regions, such as the vulva, the perianal region, the scrotum
Externí odkaz:
https://doaj.org/article/02ed4f0921e249db898877b9b34d54a9
Autor:
Francesca Ligorio, Luca Zambelli, Giovanni Fucà, Riccardo Lobefaro, Marzia Santamaria, Emma Zattarin, Filippo de Braud, Claudio Vernieri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Human Epidermal growth factor Receptor 2 (HER2) overexpression or HER2 gene amplification defines a subset of breast cancers (BCs) characterized by higher biological and clinical aggressiveness. The introduction of anti-HER2 drugs has remarkably impr
Externí odkaz:
https://doaj.org/article/9e73ed9583ae4cee885a74db768a4b79